查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1996526

失智症治疗市场：2026-2032年全球市场预测（按药物类别、治疗方法、给药途径、患者年龄层、疾病阶段、专利状态、分销管道和最终用户划分）

Dementia Drugs Market by Drug Class, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，失智症治疗市场价值将达到 119.6 亿美元，到 2026 年将成长至 132.8 亿美元，到 2032 年将达到 263.9 亿美元，复合年增长率为 11.96%。

主要市场统计数据
基准年 2025 119.6亿美元
预计年份：2026年 132.8亿美元
预测年份 2032 263.9亿美元
复合年增长率 (%) 11.96%

对当前失智症治疗现状进行全面概述，将科学进步、患者照护现实和分配复杂性联繫起来。

失智症治疗领域正处于一个转折点，新的科学发现、不断发展的护理模式以及为患者和看护者带来切实疗效的日益增长的压力共同塑造了这一局面。儘管我们对此疾病生物学机制的理解不断加深，拓展了正在研究的治疗标靶范围，但现有的症状治疗在目前的临床实践中仍然至关重要。这些并行发展的趋势要求相关人员既关注短期病患管理，也要关注长期创新路径。

对重塑失智症治疗研究、商业化、诊断和供应链方法的关键变革性变化进行详细检验。

近年来，失智症治疗领域发生了翻天覆地的变化，其影响范围和程度都发生了根本性的转变，改变了研究的优先顺序和治疗的实施方式。基于生物标记的诊断和认知衰退的早期检测正在改变干预措施的合格标准，并使更有针对性的治疗方法成为可能。诊断准确性的提高与不断发展的临床终点相互作用，促使研发人员重新思考临床试验设计和核准后证据的构建，以证明治疗对患者及其看护者的实际益处。

分析概述了近期美国关税政策如何影响整个失智症护理过程中的药品采购、生产决策和分销韧性。

美国贸易和关税政策的变化正在为全球失智症药物的生产和分销带来新的格局，其累积效应影响着製造、采购和分销管道的运作。某些医药原料进口关税的提高凸显了供应商多元化和在地化生产的重要性，迫使企业评估将关键生产过程迁回本国或外包至邻国的成本和战略意义。这些调整也对下游相关人员，包括经销商和终端用户，产生了连锁反应。

我们深入探索基于细分市场的治疗领域、分销管道、护理环境和患者群体等方面的见解，以促进临床和商业策略的发展。

细分市场层面的趋势揭示了不同治疗领域、通路、医疗机构和患者特征所面临的不同挑战，这些挑战都为药物研发和商业化策略提供了新的视角。胆碱酯酶抑制剂和NMDA受体拮抗剂等药物类别在症状管理中继续发挥核心作用，而多奈哌齐和美Memantine等药物的联合治疗则展示瞭如何利用互补的作用机制来增强临床疗效。在胆碱酯酶抑制剂中，多奈哌齐、Galantamine和Rivastigmine等药物仍在进行剂量优化、耐受性和製剂改进的评估。

全面的区域分析揭示了不同的监管环境、支付方趋势和製造地如何影响世界各地的医疗服务取得和交付。

区域趋势是失智症治疗药物研发、核准和推广的关键因素，每个地区都有其独特的法规、付款者和医疗服务体系，这些都会影响策略选择。在美洲，公共和私人支付方对报销途径有着强大的影响力，而对临床试验网络和生产製造的相对集中投资则支持了创新和快速商业化。该地区医疗基础设施的多样性要求采用高度灵活的分销模式，以满足都市区医院和社区护理的需求。

对企业层面的策略性措施进行深入分析，这些措施结合了投资组合多元化、伙伴关係、供应链改进和真实世界数据 (REW) 计划，以保持竞争优势。

失智症治疗领域中主要企业的策略重点在于产品组合多元化、策略联盟以及生命週期管理的整合方法，以应对竞争压力和临床复杂性。这些企业若能平衡对症治疗、联合治疗和新型作用机制的投资，就能更能满足患者的多元需求，同时规避风险。与学术机构、生物技术创新者和契约製造组织 (CMO) 的合作正日益普遍，成为加速研发、扩大生产能力和保障供应链的手段。

为产业领导者提供切实可行的策略建议，以协调研究重点、供应链韧性、商业化方法和以患者为中心的服务模式。

产业领导者应采取多管齐下的策略，将研发重点与商业性需求和以病人为中心的护理路径结合。优先发展生物标记驱动的研发和适应性试验设计，可以加速识别最有可能获益的患者群体；同时，对真实世界数据（REW）项目的同步投资，则能增强对支付方和医疗服务提供者的价值证明。将患者和看护者的见解融入产品设计和服务模式，可以提高用药依从性，并带来更佳的临床疗效。

对一种透明且严谨的调查方法的说明，该方法结合了相关人员访谈、文献整合、情境测试和细分映射，以检验研究结果和意义。

本分析的调查方法结合了定性和定量方法，以确保获得平衡的见解和可靠的检验。主要资料来源包括对临床医生、药剂师、支付方代表和供应链专家的结构化访谈，以了解治疗应用、分销挑战和获取限制等方面的实际观点。次要资料来源包括同侪审查文献、监管指导文件和已发表的临床试验结果，以阐明科学和政策趋势的背景。

简要概述了战略挑战，重点强调整合科学进步、持续供应和以患者为中心的实施，以改善护理结果。

总之，目前失智症的治疗现况既有延续性也有变革性。儘管诊断技术的进步和新策略正在重塑长期的创新路径，但现有的症状治疗仍具有重要的临床意义。相关人员必须平衡有针对性的研发、实证医学的累积以及对服务模式的投资，以满足病患的即时管理需求，同时也要兼顾保险公司、医疗服务提供者和看护者不断变化的期望。成功取决于将严谨的科学研究与切实可行的营运计划结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：失智症治疗市场：依药物类别划分

  • 胆碱酯酶抑制剂
    • 多奈哌齐
    • Galantamine
    • Rivastigmine

第九章：依治疗方法失智症治疗市场

  • 联合治疗
  • 单药治疗

第十章：失智症治疗市场：依给药途径划分

  • 口服
  • 经皮

第十一章：依患者年龄层分類的失智症治疗药物市场

  • 65-74岁
  • 75-84岁
  • 85岁或以上
  • 65岁以下

第十二章 依疾病阶段失智症治疗药物市场

  • 温和的
  • 缓和
  • 严重

第十三章：依专利状况分類的失智症治疗药物市场

  • 品牌商品
  • 非专利的

第十四章失智症治疗市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十五章失智症治疗市场：依最终用户划分

  • 诊所
  • 居家照护设施
  • 医院
  • 护理机构

第十六章失智症治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章失智症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章失智症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国失智症治疗市场

第二十章：中国失智症治疗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AC Immune SA
  • AstraZeneca plc
  • Axsome Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
Product Code: MRR-FD3F12D54013

The Dementia Drugs Market was valued at USD 11.96 billion in 2025 and is projected to grow to USD 13.28 billion in 2026, with a CAGR of 11.96%, reaching USD 26.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.96 billion
Estimated Year [2026] USD 13.28 billion
Forecast Year [2032] USD 26.39 billion
CAGR (%) 11.96%

A comprehensive introductory perspective on the current dementia drug environment that bridges scientific progress, patient care realities, and distribution complexities

The therapeutic landscape for dementia drugs is at an inflection point, shaped by new scientific insights, evolving care models, and intensifying pressure to deliver meaningful outcomes for patients and caregivers. Advances in understanding disease biology have broadened the range of therapeutic targets under investigation, while established symptomatic treatments remain critical to current clinical practice. These parallel trajectories demand that stakeholders maintain a dual focus on near-term patient management and longer-term innovation pathways.

Patient demographics and care delivery realities are creating added complexity for developers and providers. Diverse end users such as clinics, home care settings, hospitals, and long-term care facilities require flexible treatment options that accommodate different care capacities and administration settings. Distribution channels likewise span hospital pharmacy, online pharmacy, retail pharmacy, and specialty pharmacy, adding layers to commercialization strategies and patient access planning.

Therapeutic choices are informed by treatment type distinctions between combination therapy and monotherapy, and by route of administration considerations such as oral and transdermal options. Drug class segmentation-including cholinesterase inhibitors and NMDA receptor antagonists-continues to underpin many prescribing decisions, while combination approaches aim to improve symptom control and patient functionality. As the ecosystem adapts, stakeholders will need integrated strategies that reconcile scientific advances with practical constraints in care delivery and distribution.

A detailed examination of the major transformative shifts reshaping research, commercialization, diagnostics, and supply chain approaches in dementia therapeutics

Recent shifts in the dementia drugs landscape are transformative in both scope and implication, altering how research is prioritized and how treatments are delivered. Biomarker-driven diagnostics and earlier identification of cognitive decline are changing the eligibility criteria for interventions and enabling more targeted therapeutic approaches. This diagnostic precision interacts with evolving clinical endpoints, prompting developers to recalibrate trial designs and post-approval evidence generation to demonstrate tangible benefits for patients and caregivers.

Commercially, the balance between branded innovation and generic competition is changing how companies plan lifecycle strategies, with patent status and formulation options shaping product longevity. Digital therapeutics and remote monitoring tools are beginning to complement pharmacologic regimens, extending the role of telehealth and digital adherence programs into chronic management pathways. These shifts are also affecting distribution channels and end-user interactions, as online pharmacy services and specialty pharmacy models grow in relevance for complex or high-cost therapies.

Operationally, supply chain resilience and geographic manufacturing strategies have become strategic differentiators. Companies are reassessing sourcing for active pharmaceutical ingredients, investing in regional manufacturing capacity, and forging partnerships to secure continuity of supply. Concurrently, payer expectations are driving more rigorous value demonstration and real-world evidence collection, linking reimbursement and access to demonstrable patient outcomes and economic impact.

An analytical overview of how recent United States tariff policies are influencing pharmaceutical sourcing, manufacturing decisions, and distribution resilience across the dementia care continuum

Policy changes in trade and tariffs enacted in the United States have introduced new dynamics into the global production and distribution of dementia therapies, and the cumulative effects extend across manufacturing, procurement, and channel operations. Higher import duties on certain pharmaceutical inputs have increased the importance of supplier diversification and of localized manufacturing, prompting companies to evaluate the cost and strategic implications of reshoring or nearshoring key production steps. These adjustments have ripple effects for downstream stakeholders, including distributors and end users.

Distribution channels such as hospital pharmacy, specialty pharmacy, retail pharmacy, and online pharmacy are responding to altered cost structures and lead times. Hospitals and long-term care facilities that rely on stable supply chains may experience procurement challenges or need to renegotiate terms with suppliers. Specialty pharmacies, which often manage complex therapies and limited distribution products, are particularly sensitive to cost pass-through and logistical disruptions, and may shift sourcing strategies to mitigate exposure.

The tariffs context also affects branded and generic product strategies differently. Manufacturers of branded therapies may accelerate efforts to protect supply continuity for premium products, while generic manufacturers could face margin compression that influences production decisions. For multinational companies, regional manufacturing footprints and third-party logistics partnerships have emerged as critical levers to absorb trade policy shocks and maintain uninterrupted access for patients across care settings.

A thorough exploration of segmentation-driven insights across therapeutic class, distribution channels, care settings, and patient cohorts that inform clinical and commercial strategy

Segment-level dynamics reveal differentiated imperatives across therapeutic class, distribution pathway, care setting, and patient characteristics, each carrying implications for development and commercialization strategies. Drug classes such as cholinesterase inhibitors and NMDA receptor antagonists remain central to symptomatic management, while combination therapies that pair agents like donepezil and memantine illustrate how complementary mechanisms are being deployed to enhance clinical benefit. Within cholinesterase inhibitors, agents including donepezil, galantamine, and rivastigmine continue to be evaluated for optimized dosing, tolerability, and formulation improvements.

Distribution channels shape access and patient experience, with hospital pharmacy environments prioritizing inpatient continuity of care, retail pharmacy supporting routine outpatient dispensing, specialty pharmacy delivering complex care coordination, and online pharmacy providing convenience and adherence supports. End users ranging from clinics to home care settings, hospitals, and long-term care facilities demand different formulations and packaging solutions, and they place varying emphasis on administration ease and monitoring requirements. Treatment type distinctions between combination therapy and monotherapy influence prescribing patterns and payer negotiations, particularly in populations with comorbidities.

Route of administration choices such as oral versus transdermal delivery influence adherence profiles, tolerability, and caregiver burden, while patient age group segmentation including cohorts under 65, 65 to 74, 75 to 84, and 85 and above highlights shifting clinical priorities and comorbidity considerations. Disease stage stratification across mild, moderate, and severe dementia informs therapeutic intent, care pathways, and clinical trial design. Patent status categories of branded and generic products continue to dictate competitive dynamics and lifecycle planning, reinforcing the need for flexible commercial models that anticipate transitions in exclusivity and pricing environment.

A comprehensive regional analysis revealing how differing regulatory landscapes, payer dynamics, and manufacturing footprints shape access and delivery across global territories

Regional dynamics are a defining factor in how dementia therapies are developed, approved, and deployed, and each geographic area presents distinct regulatory, payer, and care delivery realities that shape strategic choices. In the Americas, public and private payers exert strong influence over reimbursement pathways, and clinical trial networks and manufacturing investments are relatively concentrated, supporting both innovation and rapid commercialization. Healthcare infrastructure diversity within the region necessitates adaptable distribution models that can meet the needs of urban hospitals and community-based care alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying levels of healthcare resourcing create complex market entry considerations. Pricing and reimbursement frameworks across European countries often emphasize comparative effectiveness and health technology assessment, prompting developers to invest in outcomes research and real-world evidence generation. In the MEA region, access considerations and capacity constraints influence adoption timelines, while partnerships with regional distributors and local manufacturers can improve supply reliability and patient reach.

Asia-Pacific exhibits significant heterogeneity in regulatory pathways, demographic trends, and manufacturing capacity. Several countries in the region serve as major manufacturing hubs for active pharmaceutical ingredients and finished formulations, while neighbouring markets present substantial demand driven by aging populations and expanding healthcare access. Companies operating in this region must navigate variable reimbursement systems, local clinical practice preferences, and opportunities for collaboration with regional research institutions to accelerate development and access.

An incisive review of company-level strategic moves that combine portfolio diversification, partnerships, supply chain fortification, and real-world evidence efforts to sustain competitive advantage

Key company strategies in the dementia therapeutics domain emphasize diversified portfolios, strategic partnerships, and an integrated focus on lifecycle management to navigate competitive pressures and clinical complexity. Firms that balance investment across symptomatic agents, combination therapies, and novel mechanisms can better address heterogeneous patient needs while hedging risk. Collaboration with academic centers, biotech innovators, and contract manufacturing organizations is increasingly common as a route to accelerate development, expand manufacturing capacity, and secure supply chains.

Commercial tactics include targeted engagement with specialty pharmacies and long-term care providers to optimize distribution for patients with advanced care needs, while retail and online pharmacy channels are leveraged to enhance outpatient adherence and caregiver convenience. Companies are also prioritizing outcomes and real-world data initiatives to demonstrate value to payers and health systems, supporting reimbursement discussions and formulary positioning. For organizations facing patent transitions, strategies such as reformulation, delivery innovations like transdermal patches, and indication expansion are being used to preserve therapeutic relevance.

Leadership teams are investing in digital capabilities to complement pharmacologic treatment, including adherence platforms and remote monitoring, which can strengthen value propositions for payers and providers. Additionally, firms are increasingly focused on geographic diversification of manufacturing and clinical trial enrollment to manage regulatory risk and to accelerate access across multiple regions.

Actionable strategic recommendations for industry leadership that align research priorities, supply chain resilience, commercialization approaches, and patient-centered service models

Industry leaders should adopt a multi-dimensional strategy that aligns R&D priorities with commercial imperatives and patient-centered care pathways. Prioritizing biomarker-enabled development and adaptive trial designs can accelerate identification of populations most likely to benefit, while parallel investment in real-world evidence programs will strengthen value demonstration for payers and providers. Integrating patient and caregiver insights into product design and service models enhances adherence and supports superior clinical outcomes.

Operational resilience requires proactive supply chain diversification, including assessment of alternative API suppliers, consideration of regional manufacturing footprints, and partnerships with logistics providers to manage tariff and trade uncertainties. Commercially, organizations should tailor distribution strategies to distinct channel characteristics-hospital pharmacy, retail pharmacy, specialty pharmacy, and online pharmacy-ensuring that logistical capabilities match product complexity and patient needs. Collaboration with long-term care facilities, hospitals, clinics, and home care providers is essential to streamline adoption and to address site-specific training and support requirements.

Finally, leaders should pursue value-based contracting pilots and outcomes-linked arrangements where feasible, pairing these with digital health solutions that monitor adherence and functional outcomes. This combination can reduce payer resistance, de-risk adoption, and create pathways for sustained access while demonstrating a commitment to improving patient quality of life.

A transparent and rigorous description of methodology combining stakeholder interviews, literature synthesis, scenario testing, and segmentation mapping to validate findings and implications

The research methodology underpinning this analysis blended qualitative and quantitative approaches to ensure balanced insight and robust validation. Primary inputs included structured interviews with clinicians, pharmacists, payer representatives, and supply chain experts to capture frontline perspectives on therapeutic use, distribution challenges, and access constraints. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and published clinical trial results to contextualize scientific and policy developments.

Analytical steps involved triangulating stakeholder inputs with literature findings to identify consistent themes and to reconcile divergent views. Scenario analysis was applied to stress-test supply chain and commercial strategies under different trade and regulatory conditions. In addition, segmentation maps were constructed to illuminate how drug class, distribution channel, end-user setting, treatment type, route of administration, patient age group, disease stage, and patent status interact to influence clinical and commercial outcomes.

Quality assurance procedures included expert panel review and iterative validation cycles, ensuring that conclusions reflect practical realities and clinical plausibility. The methodology prioritized transparency and reproducibility, enabling decision makers to trace insights back to source inputs and to adapt analytical frameworks for organization-specific use cases.

A concise summation of strategic imperatives that emphasizes the integration of scientific advancement, supply continuity, and patient-centered execution to improve care outcomes

In conclusion, the dementia therapeutics landscape is characterized by simultaneous continuity and change: established symptomatic agents retain clinical importance even as diagnostic advances and novel strategies reshape long-term innovation pathways. Stakeholders must balance immediate patient management needs with investments in targeted R&D, evidence generation, and delivery models that meet the evolving expectations of payers, providers, and caregivers. Success will depend on aligning scientific rigor with pragmatic operational planning.

Supply chain resilience, adaptive commercialization approaches, and cross-sector partnerships will be key to sustaining access and to translating therapeutic progress into meaningful patient impact. Regional considerations, distribution channel dynamics, and segmentation nuances underscore the need for tailored strategies that respect local regulatory and care delivery contexts. By integrating clinical insight, real-world evidence, and patient-centered design, organizations can navigate complexity and contribute to improved outcomes for people living with dementia.

The path forward will require sustained collaboration across industry, clinical, and policy stakeholders to ensure that new and existing therapies reach the patients who need them most, while maintaining affordability and continuity of care across diverse settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dementia Drugs Market, by Drug Class

  • 8.1. Cholinesterase Inhibitors
    • 8.1.1. Donepezil
    • 8.1.2. Galantamine
    • 8.1.3. Rivastigmine

9. Dementia Drugs Market, by Treatment Type

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Dementia Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Transdermal

11. Dementia Drugs Market, by Patient Age Group

  • 11.1. 65 To 74
  • 11.2. 75 To 84
  • 11.3. 85 And Above
  • 11.4. Under 65

12. Dementia Drugs Market, by Disease Stage

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Dementia Drugs Market, by Patent Status

  • 13.1. Branded
  • 13.2. Generic

14. Dementia Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy
  • 14.4. Specialty Pharmacy

15. Dementia Drugs Market, by End User

  • 15.1. Clinics
  • 15.2. Home Care Settings
  • 15.3. Hospitals
  • 15.4. Long-Term Care Facilities

16. Dementia Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Dementia Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Dementia Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Dementia Drugs Market

20. China Dementia Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AC Immune SA
  • 21.6. AstraZeneca plc
  • 21.7. Axsome Therapeutics, Inc.
  • 21.8. Cassava Sciences, Inc.
  • 21.9. Eisai Co., Ltd.
  • 21.10. Eli Lilly and Company
  • 21.11. F. Hoffmann-La Roche Ltd.
  • 21.12. H. Lundbeck A/S
  • 21.13. Johnson & Johnson
  • 21.14. Merck & Co., Inc.
  • 21.15. Novartis AG
  • 21.16. Otsuka Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DEMENTIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)